MedPath

A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged β‰₯ 60 Years

Registration Number
NCT00079105
Lead Sponsor
Newcastle-upon-Tyne Hospitals NHS Trust
Brief Summary

RATIONALE: Drugs used in chemotherapy, such as vinblastine, cyclophosphamide, procarbazine, prednisolone, etoposide, mitoxantrone, and bleomycin, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more cancer cells.

PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating older patients with previously untreated Hodgkin's lymphoma.

Detailed Description

OBJECTIVES:

Primary

* Determine the efficacy and toxicity of vinblastine, cyclophosphamide, procarbazine, prednisolone, etoposide, mitoxantrone, and bleomycin in older patients with Hodgkin's lymphoma.

* Determine whether the application of the Hasenclever prognostic index is valid in these patients at diagnosis.

OUTLINE: This is an open-label, multicenter study.

* Chemotherapy: Patients receive vinblastine IV and cyclophosphamide IV on day 1; oral procarbazine and oral prednisolone on days 1-5; oral etoposide on days 15-19; and mitoxantrone IV and bleomycin IV on day 15. Treatment repeats every 28 days, in the absence of disease progression or unacceptable toxicity, for a total of 3 courses in patients with early (stage IA or IIA) disease or 6 courses in patients with advanced (stage IB or IIB-IV) disease.

* Radiotherapy: Patients with early stage disease receive involved-field radiotherapy. Patients with advanced stage disease receive radiotherapy limited to sites of initial bulky disease or residual disease. Radiotherapy begins 4 weeks after the completion of chemotherapy.

Patients are followed monthly for 3 months, every 3 months for 6 months, and then annually thereafter.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 150 patients will be accrued for this study within 36 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
175
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Treatmentbleomycin sulfateTreatment with VEPEMB - Vinblastine sulfate, Cyclophosphamide, Procarbazine hydrochloride, Prednisolone, Etoposide, Mitoxantrone hydrochloride, and Bleomycin sulfate
TreatmentcyclophosphamideTreatment with VEPEMB - Vinblastine sulfate, Cyclophosphamide, Procarbazine hydrochloride, Prednisolone, Etoposide, Mitoxantrone hydrochloride, and Bleomycin sulfate
TreatmentetoposideTreatment with VEPEMB - Vinblastine sulfate, Cyclophosphamide, Procarbazine hydrochloride, Prednisolone, Etoposide, Mitoxantrone hydrochloride, and Bleomycin sulfate
Treatmentmitoxantrone hydrochlorideTreatment with VEPEMB - Vinblastine sulfate, Cyclophosphamide, Procarbazine hydrochloride, Prednisolone, Etoposide, Mitoxantrone hydrochloride, and Bleomycin sulfate
Treatmentvinblastine sulfateTreatment with VEPEMB - Vinblastine sulfate, Cyclophosphamide, Procarbazine hydrochloride, Prednisolone, Etoposide, Mitoxantrone hydrochloride, and Bleomycin sulfate
Treatmentprocarbazine hydrochlorideTreatment with VEPEMB - Vinblastine sulfate, Cyclophosphamide, Procarbazine hydrochloride, Prednisolone, Etoposide, Mitoxantrone hydrochloride, and Bleomycin sulfate
TreatmentprednisoloneTreatment with VEPEMB - Vinblastine sulfate, Cyclophosphamide, Procarbazine hydrochloride, Prednisolone, Etoposide, Mitoxantrone hydrochloride, and Bleomycin sulfate
Primary Outcome Measures
NameTimeMethod
Disease-free survival by routine imaging6 month intervals
Secondary Outcome Measures
NameTimeMethod
Overall survival by routine imaging5 years

Trial Locations

Locations (54)

Royal United Hospital

πŸ‡¬πŸ‡§

Bath, England, United Kingdom

Kent and Canterbury Hospital

πŸ‡¬πŸ‡§

Canterbury, England, United Kingdom

Saint Richards Hospital

πŸ‡¬πŸ‡§

Chichester, England, United Kingdom

University Hospital of North Durham

πŸ‡¬πŸ‡§

Durham, England, United Kingdom

Hull Royal Infirmary

πŸ‡¬πŸ‡§

Hull, England, United Kingdom

Kettering General Hosptial

πŸ‡¬πŸ‡§

Kettering, Northants, England, United Kingdom

Sunderland Royal Hospital

πŸ‡¬πŸ‡§

Sunderland, England, United Kingdom

Aberdeen Royal Infirmary

πŸ‡¬πŸ‡§

Aberdeen, Scotland, United Kingdom

Royal Alexandra Hospital

πŸ‡¬πŸ‡§

Paisley, Scotland, United Kingdom

Medizinische Universitaetsklinik I at the University of Cologne

πŸ‡©πŸ‡ͺ

Cologne, Germany

Wansbeck General Hospital

πŸ‡¬πŸ‡§

Ashington, England, United Kingdom

Basingstoke and North Hampshire NHS Foundation Trust

πŸ‡¬πŸ‡§

Basingstoke, England, United Kingdom

Good Hope Hospital

πŸ‡¬πŸ‡§

Birmingham, England, United Kingdom

Royal Bournemouth Hospital

πŸ‡¬πŸ‡§

Bournemouth, England, United Kingdom

Blackpool Victoria Hospital

πŸ‡¬πŸ‡§

Blackpool, England, United Kingdom

Cumberland Infirmary

πŸ‡¬πŸ‡§

Carlisle, England, United Kingdom

Bradford Royal Infirmary

πŸ‡¬πŸ‡§

Bradford, England, United Kingdom

Queen Elizabeth Hospital

πŸ‡¬πŸ‡§

Gateshead-Tyne and Wear, England, United Kingdom

Diana Princess of Wales Hospital

πŸ‡¬πŸ‡§

Grimsby, England, United Kingdom

Medway Maritime Hospital

πŸ‡¬πŸ‡§

Gillingham Kent, England, United Kingdom

Harrogate District Hospital

πŸ‡¬πŸ‡§

Harrogate, England, United Kingdom

Leeds General Infirmary

πŸ‡¬πŸ‡§

Leeds, England, United Kingdom

Ipswich Hospital

πŸ‡¬πŸ‡§

Ipswich, England, United Kingdom

Airedale General Hospital

πŸ‡¬πŸ‡§

Keighley, England, United Kingdom

Leicester Royal Infirmary

πŸ‡¬πŸ‡§

Leicester, England, United Kingdom

Maidstone Hospital

πŸ‡¬πŸ‡§

Maidstone, England, United Kingdom

University College Hospital - London

πŸ‡¬πŸ‡§

London, England, United Kingdom

Manchester Royal Infirmary

πŸ‡¬πŸ‡§

Manchester, England, United Kingdom

James Cook University Hospital

πŸ‡¬πŸ‡§

Middlesbrough, England, United Kingdom

Christie Hospital

πŸ‡¬πŸ‡§

Manchester, England, United Kingdom

University of Newcastle-Upon-Tyne Northern Institute for Cancer Research

πŸ‡¬πŸ‡§

Newcastle-Upon-Tyne, England, United Kingdom

Northern Centre for Cancer Treatment at Newcastle General Hospital

πŸ‡¬πŸ‡§

Newcastle-Upon-Tyne, England, United Kingdom

North Tyneside Hospital

πŸ‡¬πŸ‡§

North Shields, England, United Kingdom

Northampton General Hospital

πŸ‡¬πŸ‡§

Northampton, England, United Kingdom

Royal Hallamshire Hospital

πŸ‡¬πŸ‡§

Sheffield, England, United Kingdom

Mount Vernon Cancer Centre at Mount Vernon Hospital

πŸ‡¬πŸ‡§

Northwood, England, United Kingdom

Dorset Cancer Centre

πŸ‡¬πŸ‡§

Poole Dorset, England, United Kingdom

Pembury Hospital

πŸ‡¬πŸ‡§

Royal Tunbridge Wells, Kent, England, United Kingdom

Wexham Park Hospital

πŸ‡¬πŸ‡§

Slough, Berkshire, England, United Kingdom

South Tyneside District Hospital

πŸ‡¬πŸ‡§

South Shields, England, United Kingdom

Southampton General Hospital

πŸ‡¬πŸ‡§

Southampton, England, United Kingdom

Staffordshire General Hospital

πŸ‡¬πŸ‡§

Stafford, England, United Kingdom

University Hospital of North Staffordshire

πŸ‡¬πŸ‡§

Stoke-On-Trent Staffs, England, United Kingdom

Royal Cornwall Hospital

πŸ‡¬πŸ‡§

Truro, Cornwall, England, United Kingdom

West Cumberland Hospital

πŸ‡¬πŸ‡§

Whitehaven, England, United Kingdom

Cancer Care Centre at York Hospital

πŸ‡¬πŸ‡§

York, England, United Kingdom

Monklands General Hospital

πŸ‡¬πŸ‡§

Airdrie, Scotland, United Kingdom

Western Infirmary

πŸ‡¬πŸ‡§

Glasgow, Scotland, United Kingdom

Edinburgh Cancer Centre at Western General Hospital

πŸ‡¬πŸ‡§

Edinburgh, Scotland, United Kingdom

Raigmore Hospital

πŸ‡¬πŸ‡§

Inverness, Scotland, United Kingdom

Barnet General Hospital

πŸ‡¬πŸ‡§

Barnet, Hertfordshire, United Kingdom

Wishaw General Hospital

πŸ‡¬πŸ‡§

Wishaw, Scotland, United Kingdom

Trafford General Hospital

πŸ‡¬πŸ‡§

Manchester, England, United Kingdom

Royal Liverpool University Hospital

πŸ‡¬πŸ‡§

Liverpool, England, United Kingdom

Β© Copyright 2025. All Rights Reserved by MedPath